イスラエル - ヘブライ語 - Ministry of Health

bayer israel ltd - rivaroxaban micronized - טבליות מצופות פילם - rivaroxaban micronized 20 mg - rivaroxaban - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age?75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

イスラエル - ヘブライ語 - Ministry of Health

bayer israel ltd - rivaroxaban micronized - טבליות מצופות פילם - rivaroxaban micronized 20 mg - rivaroxaban - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age?75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

イスラエル - ヘブライ語 - Ministry of Health

cts ltd - progesterone micronized - קפסולות - progesterone micronized 200 mg - progesterone - progesterone - vaginal administration: progesterone substitution for ovary deprived women in situation of total progesterone deficiency. supplementation of the luteal phase during in vitro fertilization cycles. supplementation of the luteal phase during spontaneous or induced cycles, in cases of hypofertility or primary or secondary ovarain failure, particulary through dysovulation. in cases of threatning abortion or prevention of repeated abortions due to proven luteal insufficiency. for all other progesterone indication, in the case of : adverse events due to progesterone, contraindication of the oral route of administration hepatopathy. vaginal or oral addministration: disorders related to progesterone deficit in particular menopause ( in association with estrogen therapy).

イスラエル - ヘブライ語 - Ministry of Health

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 80 mcg/dose; formoterol fumarate 4.5 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - symbicort turbuhaler is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequaterly controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. - or patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. note: symbicort turbuhaler 80/4.5 mcg/dose is not appropriate in patients with severe asthma.

イスラエル - ヘブライ語 - Ministry of Health

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 160 mcg/dose; formoterol fumarate 4.5 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - asthma symbicort turbuhaler is indicated in the regular treatment of asthma in adults and adolescents age 12 years and above where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. or - patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. copd symptomatic treatment of patients with severe copd (fev1 < 50 % predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular therapy with long-acting bronchodilators.

イスラエル - ヘブライ語 - Ministry of Health

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 320 mcg/dose; formoterol fumarate 9 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - symbicort turbuhaler is indicated in the regular treatment of asthma in adults and adolescents (over the age of 12 years) where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequaterly controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. - or patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. copd symptomatic treatment of patients with severe copd (fev1 < 50 % predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular therapy with long-acting bronchodilators.

イスラエル - ヘブライ語 - Ministry of Health

cts ltd - progesterone micronized - קפסולות - progesterone micronized 200 mg - progesterone

イスラエル - ヘブライ語 - Ministry of Health

bayer israel ltd - rivaroxaban micronized - טבליות מצופות פילם - rivaroxaban micronized 15 mg - rivaroxaban

イスラエル - ヘブライ語 - Ministry of Health

bayer israel ltd - rivaroxaban micronized - טבליות מצופות פילם - rivaroxaban micronized 15 mg - rivaroxaban

イスラエル - ヘブライ語 - Ministry of Health

bayer israel ltd - rivaroxaban micronized - טבליות מצופות פילם - rivaroxaban micronized 20 mg - rivaroxaban